Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Operating Expenses (2020 - 2025)

NeuroPace has reported Operating Expenses over the past 6 years, most recently at $22.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $22.3 million for Q4 2025, up 12.62% from a year ago — trailing twelve months through Dec 2025 was $93.6 million (up 15.85% YoY), and the annual figure for FY2025 was $93.6 million, up 15.85%.
  • Operating Expenses for Q4 2025 was $22.3 million at NeuroPace, down from $23.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for NPCE hit a ceiling of $25.0 million in Q2 2025 and a floor of $12.4 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $18.7 million (2022), compared with a mean of $19.0 million.
  • Peak annual rise in Operating Expenses hit 57.48% in 2021, while the deepest fall reached 1.18% in 2021.
  • NeuroPace's Operating Expenses stood at $17.1 million in 2021, then grew by 9.19% to $18.7 million in 2022, then dropped by 0.35% to $18.6 million in 2023, then grew by 6.69% to $19.8 million in 2024, then grew by 12.62% to $22.3 million in 2025.
  • The last three reported values for Operating Expenses were $22.3 million (Q4 2025), $23.8 million (Q3 2025), and $25.0 million (Q2 2025) per Business Quant data.